ClinicalTrials.gg
Active, not recruitingNCT06360458MIRACLEUpdated Dec 3, 2025

Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke

A Phase 3 interventional study of Methylprednisolone sodium succinate and Placebo in Acute Ischemic Stroke and Large Infarct Core, sponsored by Wan-Jin Chen. Active, not recruiting at 99 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Wan-Jin Chen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
928
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Enrollment
116th of 566
928 · median 271
Started
2024
with 102 others
Phase 3
111 of 754
65 open now
Primary completion
2025-09
later than 62 of 399 live
Registered
451st of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 116th largest by enrollment of the 566 interventional ones that give a count, is one of 103 that started in 2024, is one of 111 in phase 3, reaches primary completion later than 62 of the 399 other live ones, and was the 451st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

The efficacy and safety of methylprednisolone in acute ischemic stroke patients with large infarct cores (ASPECTS score \< 6 or infarct volume ≥50 mL) due to anterior circulation large vessel occlusion have not been clearly established. This is a multi-center, randomized, double-blind, placebo-controlled trial to investigate early combination therapy with methylprednisolone for reperfusion in acute large core infarction.

03

Conditions studied

  • Acute Ischemic Stroke
  • Large Infarct Core

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • The time from onset to randomization was within 12 hours.
  • Anterior circulation ischemic stroke was preliminarily determined according to clinical symptoms or imaging examination.
  • Occlusion of the intracranial internal carotid artery, the M1- or M2-segment of the middle cerebral artery by confirmed by CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA).
  • Baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 6.
  • Baseline Alberta Stroke Program Early CT Score (ASPECTS) \< 6 (based on non-contrast CT or MRI) and/or core infarct volume ≥ 50 ml (based on CTP with rCBF \< 30%).
  • Planned treatment with endovascular thrombectomy (EVT).
  • obtained from patients or their legal representatives.

Exclusion criteria

Exclusion Criteria:

  • Intracranial hemorrhage confirmed by cranial CT or MRI.
  • mRS score > 2 before onset.
  • Pregnant or lactating women.
  • Allergic to contrast agents or .
  • Participating in other clinical trials.
  • The artery is tortuous so that the thrombectomy device cannot reach the target vessel.
  • Bleeding history (gastrointestinal and urinary tract bleeding) in recent 1 month.
  • Chronic hemodialysis and severe renal insufficiency ( \< 30 ml/min or serum creatinine > 220 umol/L [2.5 mg/ dL]).
  • due to any advanced disease \< 6 months.
  • Follow-up is not expected to be completed.
  • Intracranial aneurysm and arteriovenous malformation.
  • Brain tumors with imaging mass effect.
  • Systemic infectious disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
928 participants (actual)

Study arms

  • Experimental
    Methylprednisolone sodium succinate group
  • Placebo comparator
    Placebo group

    Methylprednisolone sodium succinate simulant

    Drug: Placebo

Interventions

  • DrugMethylprednisolone HemisuccinateStudies of Methylprednisolone HemisuccinateMethylprednisolone Hemisuccinate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous injection of methylprednisolone sodium succinate (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.

  • DrugPlacebo

    Intravenous injection of placebo (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.

06

What researchers measure

Primary outcomes

  1. All-cause mortality at 90 (±14) days

    Primary Efficacy Outcome. Defined as the number of any cause deaths observed divided by the number of subjects observed over the 90-day study period.

    Time frame: From randomization to 90 (±14) days

Secondary outcomes

  1. Time from randomization to the occurrence of death from any cause at 90 (±14) days

    Secondary Efficacy Outcome; To evaluate death rate of the two treatment groups

    Time frame: From randomization to 90 (±14) days

  2. mRS ordinal shift at 90 (±14) days (scores 5 and 6 are merged)

    Secondary Efficacy Outcome

    Time frame: From randomization to 90 (±14) days

  3. Proportion of patients with mRS score 0 to 4 at 90 (±14) days

    Secondary Efficacy Outcome

    Time frame: From randomization to 90 (±14) days

  4. Proportion of patients with mRS score 0 to 3 at 90 (±14) days

    Secondary Efficacy Outcome

    Time frame: From randomization to 90 (±14) days

  5. Proportion of patients with mRS score 0 to 2 at 90 (±14) days

    Secondary Efficacy Outcome

    Time frame: From randomization to 90 (±14) days

  6. Proportion of patients with mRS score 0 to 1 at 90 (±14) days or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)

    Secondary Efficacy Outcome

    Time frame: From randomization to 90 (±14) days

  7. Midline shift at 48 hours

    Secondary Efficacy Outcome

    Time frame: From randomization to 48 hours

  8. Proportion of patients with midline shift >5 mm within 48 hours after EVT

    Secondary Efficacy Outcome

    Time frame: From randomization to 48 hours

  9. Relative hemispheric volume at 48 hours

    Secondary Efficacy Outcome.

    Time frame: From randomization to 48 hours

  10. Net water uptake at 48 hours

    Secondary Efficacy Outcome

    Time frame: From randomization to 48 hours

  11. Proportion of patients with decompressive craniectomy after EVT

    Secondary Efficacy Outcome

    Time frame: From randomization until the date of discharge, an average of 1 week

  12. NIHSS score at 5-7 days or at early discharge

    Secondary Efficacy Outcome

    Time frame: From randomization to 5-7 days ( or at early discharge)

  13. EQ-5D-5L VAS at 90 (±14) days

    Secondary Efficacy Outcome

    Time frame: From randomization to 90 (±14) days

  14. Proportion of patients with symptomatic intracranial haemorrhage (SICH) within 48 hours after EVT

    Primary Safety Outcome. Based on the modified Heidelberg Bleeding Classification.

    Time frame: From randomization to 48 hours

  15. Proportion of patients with any intracranial haemorrhage (ICH) within 48 hours after EVT

    Secondary Safety Outcome. Based on the modified Heidelberg Bleeding Classification.

    Time frame: From randomization to 48 hours

  16. Proportion of patients with pneumonia

    Secondary Safety Outcome

    Time frame: From randomization until the date of discharge, an average of 1 week

  17. Proportion of patients with gastrointestinal haemorrhage within 7 days after EVT

    Secondary Safety Outcome

    Time frame: From randomization to 7 days

  18. Incidence of any complications

    Secondary Safety Outcome

    Time frame: From date of randomization until the date of discharge, an average of 1 week

  19. Incidence of any (serious) adverse events

    Secondary Safety Outcome

    Time frame: From randomization to 90 (±14) days

Other outcomes

  1. mRS ordinal shift at 1 year (scores 5 and 6 are merged)

    Tertiary Efficacy Outcome

    Time frame: From randomization to 1 year

  2. Proportion of patients with mRS score 0 to 2 at 1 year

    Tertiary Efficacy Outcome

    Time frame: From randomization to 1 year

  3. Proportion of patients with mRS score 0 to 1 at 1 year or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)

    Tertiary Efficacy Outcome

    Time frame: From randomization to 1 year

  4. mRS ordinal shift at 5 years (scores 5 and 6 are merged)

    Tertiary Efficacy Outcome

    Time frame: From randomization to 5 years

  5. Proportion of patients with mRS score 0 to 2 at 5 years

    Tertiary Efficacy Outcome

    Time frame: From randomization to 5 years

  6. Proportion of patients with mRS score 0 to 1 at 5 years or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)

    Tertiary Efficacy Outcome

    Time frame: From randomization to 5 years

  7. EQ-5D-5L VAS at 1 year

    Tertiary Efficacy Outcome

    Time frame: From randomization to 1 year

  8. EQ-5D-5L VAS at 5 years

    Tertiary Efficacy Outcome

    Time frame: From randomization to 5 years

07

Study locations

99 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Sep 2025, 13 months.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 13 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2024
First posted
Apr 11, 2024
StartActual
Aug 1, 2024
Primary completionActual
Sep 30, 2025
CompletionEst.
Jun 30, 2030
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06360458
Lead sponsor
Wan-Jin Chen
Responsible party
Wan-Jin Chen (Vice President of Fujian Medical University and Vice President of The First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital of Fujian Medical University) — Sponsor-investigator
First posted
Apr 11, 2024
Start date
Aug 1, 2024
Primary completion
Sep 30, 2025
Completion
Jun 30, 2030 (estimated)
Last update
Dec 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylprednisolone Hemisuccinate

Start the discussion